BioHarvest Sciences' VINIA gains traction with top spot in US nutraceutical category

Impact · against what's priced in

BioHarvest Sciences establishes a concrete valuation baseline by reporting $30 million in 2025 US revenue and cumulative global revenue of $85 million. The claim of being the top-selling resveratrol brand in the US, backed by 85,000 active users, provides evidence of scalability and product-market fit for its Botanical Synthesis platform.

BHST+0.60

No priced-in read yet

In context

The company provides hard revenue figures ($30M US FY2025, $85M cumulative global) and a specific customer base of 85,000, transforming speculative technology potential into documented commercial traction.

Read from the article alone

• biotech
• BHST
• botanical synthesis
• direct to consumer
• e commerce
• health tech
• nutraceuticals
• pharma
• resveratrol

Search tags